The current OHSU Single Photon Emission Computed Tomography (SPECT) protocol for 177Lu radiopharmaceutical dosimetry takes roughly 1 hour, which is difficult for both pat [...]

Lutetium-177 vipivotide tetraxetan (Lu-177 PSMA-617) therapy is an effective treatment for patients with metastatic prostate cancer, although with potential adverse effec [...]